Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Free Cash Flow: 2022-2025

Historic Free Cash Flow for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$30.5 million.

  • Stoke Therapeutics' Free Cash Flow fell 40.43% to -$30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year increase of 161.83%. This contributed to the annual value of -$87.1 million for FY2024, which is 5.29% down from last year.
  • Stoke Therapeutics' Free Cash Flow amounted to -$30.5 million in Q3 2025, which was down 19.24% from -$25.6 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Free Cash Flow registered a high of $131.7 million during Q1 2025, and its lowest value of -$30.5 million during Q3 2025.
  • For the 3-year period, Stoke Therapeutics' Free Cash Flow averaged around -$8.6 million, with its median value being -$21.9 million (2023).
  • In the last 5 years, Stoke Therapeutics' Free Cash Flow crashed by 169.20% in 2023 and then spiked by 635.74% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Free Cash Flow (Quarterly) stood at -$22.8 million in 2022, then increased by 8.36% to -$20.9 million in 2023, then dropped by 11.29% to -$23.2 million in 2024, then slumped by 40.43% to -$30.5 million in 2025.
  • Its last three reported values are -$30.5 million in Q3 2025, -$25.6 million for Q2 2025, and $131.7 million during Q1 2025.